Posted on

Understanding neurodiversity

COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults

COMPASS Pathways (CMPS) is funding a psilocybin study to better understand the brain science of neurodiversity.

Using brain imaging and behavioural tasks, researchers will investigate how psilocybin affects the serotonin brain networks in autistic adults compared to non-autistic adults. 

The goal is to understand the unique brain mechanisms associated with autism to provide “better tailored choices” to autistic people.

CMPS shares spiked 11% yesterday after the company announced Q1 financial results, including $21.2M net loss and $243.7M in cash.

PDF of article

Posted on

How ketamine affects the brain over time

Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain

The results from Cybin and Kernel’s brain imaging study are in!

The findings suggest that a single dose of ketamine has a lasting effect on the way information flows through the brain.

Subjects’ brain activity patterns were relatively stable for 5 days leading up to the ketamine session.

After a low dose of ketamine, there were significant changes in functional connectivity lasting at least 5 days. 

Top images: Johnson’s absolute functional connectivity for minutes 5-15 after he received the 57.75mg intramuscular injection of Ketamine. Bottom images: Johnson’s relative functional connectivity changes after the Ketamine took effect starting at minutes 15-25. (Graphic: Business Wire)

PDF of article

Posted on

Participate in psychedelic research

If you’ve been wanting to try psychedelic therapy legally, now’s your chance!

Johns Hopkins is recruiting participants for a number of psilocybin studies on:

Plus, Nova Mentis is recruiting both autisitc and neurotypical patients for an observational study that will lead to a psilocybin microdosing study.

If you want to contribute to psychedelic research from home, check out Johns Hopkins’ online surveys on psychedelics and breathwork for anxiety, depression, and PTSD.

Posted on

How to have a safe solo trip

Psilo Psoirée is an online community that allows psychedelic explorers to connect before and after their journeys.

With a monthly membership, you’ll receive:

  • A super informative guide on how to have a safe solo trip
  • Access to monthly pre-journey “lift-off” and post-journey “landing” calls
  • Support on all things mushroom – from navigating a spiritual awakening to DIY mushroom cultivation

Use code DAILYMUSHROOM22 to get a 2-month membership for FREE!

Posted on

How to avoid adverse reactions to psychedelics

Large survey suggests psilocybin is a “relatively safe” drug, with serious reactions being rare and short-lived

A survey of over 9,200 psilocybin mushroom users found that only 0.2% have sought emergency medical treatment following use.

The most common reported reasons for these adverse experiences were:

  • Mixing substances
  • Poor mindset
  • Poor setting

Additionally, those in the emergency care-seeking group were significantly younger than the group that didn’t seek care, with a median age of 19 compared to 23.

Keep this in mind if you’re considering trying psilocybin!

PDF of article

Posted on

COMPASS announces new psilocybin therapy findings

COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression

New studies suggest that COMPASS Pathways’ proprietary psilocybin has promise in treating some of the most challenging mental health conditions: severe treatment-resistant depression and anorexia nervosa.

After a single dose of psilocybin, 58.3% of patients with severe treatment-resistant depression (meaning they’d tried 5+ antidepressant treatments without success) had a reduction in depression scores for 12 weeks.

One quarter of patients no longer qualified for a depression diagnosis.

In the anorexia study, 30% of patients had significant reductions in symptoms at the 1-month follow up, increasing to 40% at the 3-month follow up.

PDF of article

Posted on

Field Trip splits up

Field Trip Health Ltd. Announces Intention to Separate the Field Trip Discovery and Field Trip Health Divisions Into Two Independent Public Companies

Field Trip Health (FTRP) is separating into two independent public companies. Its drug discovery division will become Reunion Neuroscience Inc. and its client care division will be renamed Field Trip Health and Wellness Ltd. The separation allows each company to establish distinct capital structures and management teams that are suited to their unique strategies.

PDF of article

Posted on

Unsatisfied with life?

A single dose of 5-MeO-DMT produces rapid and persistent improvements in life satisfaction and psychopathological symptoms

A Maastricht University study found that a single dose of 5-MeO-DMT (the psychedelic found in toad venom and several plants) improved subjects’ scores for life satisfaction, depression, anxiety, and mindfulness. 

The changes were seen 1 day after the dose and persisted for 4 weeks.

Higher levels of ego dissolution were linked with greater improvements in scores (so, the more intense the trip, the more beneficial).

A separate survey found that ~80% of people with depression or anxiety reported improvements in symptoms following a dose of 5-MeO-DMT.

Some companies that are researching 5-MeO-DMT include GH Research (GHRS), Biomind Labs (BMND), and Mindset Pharma (MSET).

PDF of article

PDF of study

Posted on

Psilocybin churches in Oregon

Can a Religious Exemption Boost Legal Psilocybin Access in Oregon?

Attorney Jon Dennis submitted a proposal to Oregon’s advisory board that would allow spiritual and religious groups to become licensed as psilocybin service centers and hold group ceremonies.

Allowing these organizations to administer psilocybin therapy would make the treatment more accessible and affordable for those in need.

“It’s creating more space for these psilocybin [organizations] to exist without having to be in the underground,” says Rebecca Martinez, executive director of a psychedelic training program called Alma Institute.

PDF of article